| Economic impact of GPIIB/IIIA blockade after high-risk angioplasty: results from the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. | |
| | |
MedLine Citation:
|
PMID: 10520791 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: This study was conducted to assess the impact of GPIIb/IIIa blockade with tirofiban on costs during the initial hospitalization and at 30 days among patients undergoing high-risk coronary angioplasty. BACKGROUND: GPIIb/IIIa blockers are a new class of compounds that have been shown in clinical studies to prevent complications after high-risk angioplasty. METHODS: The RESTORE trial was a multinational, blinded placebo-controlled study of 2,197 patients randomized to tirofiban or placebo following coronary angioplasty. This economic assessment was a prospective substudy of the RESTORE trial, and included 1,920 patients enrolled in the U.S. Costs were estimated for the U.S. cohort based on their utilization of healthcare resources and on costs measured directly in 820 U.S. patients at 30 sites. RESULTS: There was a 36% difference in the rate of the composite event of death, myocardial infarction (MI) and revascularization at two days between tirofiban and placebo (8% vs. 12%, p = 0.002). This difference was attributed to a reduction in nonfatal MI, repeat angioplasty, coronary surgery and stent placement. These clinical benefits followed a similar trend at 30 days, with a 16% reduction in the composite event (p = 0.10). In-hospital cost, including professional and study drug costs, was $12,145 +/- 5,882 with placebo versus $12,230 +/- 5,527 with tirofiban (p = 0.75). The 30-day cost was $12,402 +/- 6,147 with placebo versus $12,446 +/- 5,814 with tirofiban (p = 0.87). CONCLUSIONS: Tirofiban has been shown to decrease in-hospital and possibly 30-day events after high-risk angioplasty. The beneficial clinical effects of tirofiban in high-risk patients can be achieved at no increased cost. |
| | |
Authors:
|
W S Weintraub; S Culler; S J Boccuzzi; J R Cook; A S Kosinski; D J Cohen; J Burnette |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of the American College of Cardiology Volume: 34 ISSN: 0735-1097 ISO Abbreviation: J. Am. Coll. Cardiol. Publication Date: 1999 Oct |
Date Detail:
|
Created Date: 1999-10-27 Completed Date: 1999-10-27 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8301365 Medline TA: J Am Coll Cardiol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1061-6 Citation Subset: AIM; IM |
Affiliation:
|
Emory Center for Outcomes Research, Department of Medicine, Emory University, Atlanta, Georgia 30322, USA. bill@hp3.eushc.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Angioplasty, Transluminal, Percutaneous Coronary / economics* Cohort Studies Combined Modality Therapy Coronary Disease / economics*, mortality, therapy Cost-Benefit Analysis Double-Blind Method Female Hospital Mortality Humans Male Middle Aged Myocardial Infarction / economics, mortality, therapy Platelet Aggregation Inhibitors / economics*, therapeutic use Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors* Recurrence Retreatment Risk Factors Tyrosine / analogs & derivatives*, economics, therapeutic use United States |
| Chemical | |
Reg. No./Substance:
|
0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 144494-65-5/tirofiban; 55520-40-6/Tyrosine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Final results of the STent versus directional coronary Atherectomy Randomized Trial (START)
Next Document: Periprocedural quantitative coronary angiography after Palmaz-Schatz stent implantation predicts the...